Literature DB >> 33763700

Inherited glycosylphosphatidylinositol defects cause the rare Emm-negative blood phenotype and developmental disorders.

Romain Duval1,2,3,4, Gaël Nicolas4,5, Alexandra Willemetz1,2,3,4, Yoshiko Murakami6, Mahmoud Mikdar1,2,3,4, Cedric Vrignaud1,2,3,4, Hisham Megahed7, Jean-Pierre Cartron2, Cecile Masson8, Samer Wehbi9, Bérengere Koehl1,2,3, Marie Hully10, Karine Siquier11, Nicole Chemlay12, Agnes Rotig12, Stanislas Lyonnet12, Yves Colin1,2,4, Giulia Barcia11, Vincent Cantagrel11, Caroline Le Van Kim1,2,4, Olivier Hermine4,12, Taroh Kinoshita6, Thierry Peyrard1,2,3,4, Slim Azouzi1,2,3,4.   

Abstract

Glycosylphosphatidylinositol (GPI) is a glycolipid that anchors >150 proteins to the cell surface. Pathogenic variants in several genes that participate in GPI biosynthesis cause inherited GPI deficiency disorders. Here, we reported that homozygous null alleles of PIGG, a gene involved in GPI modification, are responsible for the rare Emm-negative blood phenotype. Using a panel of K562 cells defective in both the GPI-transamidase and GPI remodeling pathways, we show that the Emm antigen, whose molecular basis has remained unknown for decades, is carried only by free GPI and that its epitope is composed of the second and third ethanolamine of the GPI backbone. Importantly, we show that the decrease in Emm expression in several inherited GPI deficiency patients is indicative of GPI defects. Overall, our findings establish Emm as a novel blood group system, and they have important implications for understanding the biological function of human free GPI.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33763700     DOI: 10.1182/blood.2020009810

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  2 in total

Review 1.  Erythroid Cell Research: 3D Chromatin, Transcription Factors and Beyond.

Authors:  Charlotte Andrieu-Soler; Eric Soler
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

2.  When recombinant proteins can replace rare red cells in immunohematology workups.

Authors:  Willy A Flegel; Kshitij Srivastava
Journal:  Transfusion       Date:  2021-05-31       Impact factor: 3.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.